Scientific topics
Keywords
Gilles LAMBERT PhD Molecular and Cellular Physiology
Course and current status
Associate Professor - University of Nantes Medical School, 2002-2011
- Inserm U957 laboratory, Nantes, France, 2010-ongoing
Comparative study of vascular calcificationsand atheroma lesions. Cardiovascular benefits of PCSK9 inhibition.
- Heart Research Institute, Sydney, Australia 2006-2010.
Characterization of PCSK9 missense mutations associated with hypercholesterolemia. Study on fenofibrate mediated down-regulation of plasma PCSK9 levels in diabetic patients. Assessment of the anti-inflammatory properties of a new generation apoA-I mimetic peptide in vivo
- Inserm U539 laboratory, Nantes, France 2002-2006.
Study of PCSK9 a new gene involved in hypercholesterolemia by adenoviral transfer in mice. Characterization of dyslipemia and atherogenesis in FXR deficient mice. Study of apolipoprotein A-IV gene expression
Scientific summary
Post doctoral fellow - National Institutes of Health, 1998-2002
- Molecular Disease Branch, Bethesda, Maryland, USA
Identification of the interactions between Hepatic Lipase and SR-BI in cultured cells and in vivo. Characterization of atherosclerosis and glomerulosclerosis in LCAT knockout mice. Generation of ABCA1 transgenic mice: Lipoprotein metabolism and atherosclerosis susceptibility. Characterization of the lipid profile of mice deficient for the nuclear hormone receptors FXR, HNF4, C/EBPa, PPARb and PPARg.
PhD student - University of Paris VI, 1994-1998.
- InsermU515 laboratory, Paris, France
Evaluation of the physicochemical properties of apolipoprotein A-II. Identification of the interaction between apoA-II, apoA-I and HDL cholesterol esterification by LCAT. Characterization of human apoA-II transgenic mice, an animal model of hypertriglyceridemia
